rs10010131 — WFS1 WFS1 Intron 4 T2D Risk Variant

Intronic variant in WFS1 (wolframin) on chromosome 4q22, one of the earliest and most replicated common genetic risk factors for type 2 diabetes, acting through ER stress dysregulation in pancreatic beta cells; the protective A allele tags a haplotype associated with preserved beta-cell insulin secretion

See your personal result for WFS1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

WFS1 — The ER Stress Guardian of the Pancreatic Beta Cell

Deep in the endoplasmic reticulum of every insulin-producing beta cell sits a protein called wolframin11 wolframin
WFS1 protein — a multi-pass transmembrane glycoprotein of the ER membrane that regulates calcium homeostasis and the unfolded protein response (UPR) in high-secretory-demand cells. The gene encoding it, WFS1, was first linked to the rare and severe Wolfram syndrome — a form of juvenile-onset non-autoimmune diabetes combined with optic atrophy, diabetes insipidus, and deafness. But beginning in 2007, genome-wide association studies revealed that common non-coding variants in WFS1 also influence type 2 diabetes risk in the general population, acting through the same beta-cell ER stress pathway — just at a milder, modulatory level rather than a catastrophic one.

The SNP rs10010131 is an intronic variant in WFS1 on chromosome 4q22 and is among the most replicated common T2D risk signals in the gene, studied in 86+ publications and replicated across European, Asian, and South American populations. The G allele (~62.5% globally) tags a haplotype associated with subtly reduced WFS1 expression or function in beta cells; the A allele (~37.5%) is protective.

The Mechanism

Beta cells are the most secretory cells in the body — they synthesize and fold enormous amounts of insulin protein through the ER every hour. This extraordinary secretory burden creates constant mild ER stress that beta cells manage through the unfolded protein response22 unfolded protein response
UPR — a three-branch cellular signaling system (IRE1α, PERK, ATF6) that detects misfolded proteins in the ER and orchestrates adaptive responses to restore protein folding homeostasis. WFS1 is a critical UPR regulator: it is directly induced by ER stress, helps clear accumulated misfolded proteins, and suppresses the Chop-Trib3 apoptotic pathway that destroys beta cells when ER stress becomes chronic.

When WFS1 expression or function is reduced — as in carriers of the G-allele haplotype — beta cells handle the daily insulin production load less efficiently. Abreu et al. 202033 Abreu et al. 2020
Abreu D et al. Wolfram syndrome 1 gene regulates pathways maintaining beta-cell health and survival. Lab Invest, 2020 showed that WFS1 depletion reduces glucose-stimulated insulin secretion and insulin content, and that WFS1 levels are measurably reduced in T2DM islets — indicating a role in common T2D independent of the monogenic syndrome. Fonseca et al. 200544 Fonseca et al. 2005
Fonseca SG et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem, 2005 demonstrated that WFS1 inactivation in beta cells triggers ER stress and dysfunction even in otherwise healthy cells.

The Evidence

Association of rs10010131 with T2D risk has been demonstrated across independent cohorts and meta-analyses with strong statistical support.

The Franks et al. 2008 Diabetologia study55 Franks et al. 2008 Diabetologia study
Franks PW et al. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia, 2008 analyzed rs10010131 in a Swedish case-control cohort (1,296 T2D cases, 1,412 controls) and subsequently combined results across 11 studies totaling up to 14,139 cases and 16,109 controls. The per-A-allele OR was 0.87 (95% CI 0.82–0.93, p = 4.5×10⁻⁵) across the meta- analysis — equivalent to a per-G-allele T2D risk OR of ~1.15.

The Fawcett et al. 2010 Diabetes study66 Fawcett et al. 2010 Diabetes study
Fawcett KA et al. Detailed investigation of the role of common and low-frequency WFS1 variants in type 2 diabetes risk. Diabetes, 2010 performed deep fine-mapping of the WFS1 locus, identifying rs1046320 as a newly associated variant with OR 0.84 (p = 6.59×10⁻⁷). This variant is in high LD with rs10010131 (r² = 0.92), and the overall OR for rs10010131 was 0.854 (95% CI 0.800–0.912, p = 2.58×10⁻⁶) — consistent across multiple independent replication cohorts.

The Cheng et al. 2013 meta-analysis77 Cheng et al. 2013 meta-analysis
Cheng S et al. Association of rs734312 and rs10010131 polymorphisms in WFS1 gene with type 2 diabetes mellitus: a meta-analysis. Endocr J, 2013 pooled 12 studies comprising 16,304 T2D cases and 22,004 controls, confirming the dominant-model OR of 0.853 (95% CI 0.817–0.892) for the protective A allele. This represents ~15% reduced T2D risk per A allele carried, or equivalently, ~17% increased risk per G allele.

Practical Implications

The WFS1 G-allele haplotype impairs T2D risk through the insulin secretion axis — specifically by increasing the ER stress burden on beta cells over time. Unlike insulin-resistance pathway variants, this effect operates upstream of insulin release itself. Chronically high secretory demand (from frequent large carbohydrate loads or persistent hyperglycemia) progressively exhausts the ER stress capacity of beta cells with reduced WFS1 function, accelerating the transition from compensated beta-cell stress to secretory failure.

The most direct dietary implication is reducing the secretory burden on beta cells: lower-glycemic-index carbohydrates, spread across meals, produce slower glucose rises that demand a smaller, more gradual insulin secretion response. Periodic metabolic monitoring is also particularly valuable here because ER stress-mediated beta-cell damage accumulates silently over years before glucose levels become overtly abnormal.

Interactions

rs10010131 is in moderate LD with rs734312 (WFS1 missense p.Arg611His), and both variants are part of the same protective haplotype studied in Russian and European cohorts 88 Chistiakov DA et al. A WFS1 haplotype consisting of minor alleles of rs752854, rs10010131, and rs734312 shows a protective role against type 2 diabetes in Russian patients. Rev Diabet Stud, 2010.

The most clinically significant interaction is with rs1884613 in the HNF4A P2 promoter region. HNF4A is the master transcription factor that drives WFS1 expression specifically in beta cells via its P2 promoter. The Neuman et al. 2010 PLoS One study99 Neuman et al. 2010 PLoS One study
Neuman RJ et al. Gene-gene interactions lead to higher risk for development of type 2 diabetes in an Ashkenazi Jewish population. PLoS One, 2010 demonstrated that subjects carrying both the HNF4A risk allele (rs1884613) and the WFS1 G allele (rs10010131) had 3-fold higher T2D odds (OR 3.0, 95% CI 1.7–5.3, P ≤ 0.0001) than those carrying neither — substantially exceeding the additive individual effects. This compound interaction reflects a regulatory double-hit: reduced HNF4A-P2 activity in beta cells may directly suppress WFS1 transcription, compounding ER stress dysregulation.

Nutrient Interactions

carbohydrate altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Genotype Beneficial

Two protective alleles — full WFS1 expression, lowest ER-stress T2D risk at this locus

You carry two copies of the A allele at WFS1 rs10010131. This is the protective haplotype associated with normal to higher WFS1 expression and full ER stress management capacity in beta cells. About 14% of people globally share this genotype, making it relatively uncommon — and particularly rare in East Asian populations where the G allele runs at ~92%.

Your genotype at this locus is not associated with elevated type 2 diabetes risk through the WFS1 pathway. Your beta cells carry a genetic advantage in managing the chronic ER stress of insulin production.

AG Intermediate Risk Intermediate

One risk allele — modestly elevated T2D risk via WFS1 ER stress pathway

With one G allele and one A allele, your WFS1 expression in beta cells falls in the intermediate range. The meta-analytic dominant-model OR of 0.853 for the A allele (Cheng et al. 2013, PMID 23257691 — 12 studies, 16,304 T2D cases) translates to an approximately 15–17% relative risk increase for G carriers compared to AA homozygotes.

In practical terms, your beta cells can manage normal physiological ER stress adequately, but sustained high secretory demand — from repeated large glucose loads — adds incremental stress over years. The risk at this locus is additive with other T2D GWAS signals acting through both the secretion and resistance axes.

GG Elevated Risk High Risk

Two risk alleles — reduced WFS1 expression, elevated ER stress T2D risk

Two G alleles produce the maximal reduction in the WFS1 protective haplotype effect. At the molecular level, GG beta cells experience higher baseline ER stress burden during insulin biosynthesis, with reduced capacity for the UPR-mediated adaptive responses WFS1 normally orchestrates. Over years of chronic dietary glucose loading, this compounds beta-cell exhaustion more rapidly than in A-allele carriers.

The Fawcett et al. 2010 deep fine-mapping study (PMID 20028947) confirmed rs10010131 overall OR of 0.854 for the A allele (p = 2.58×10⁻⁶) across multiple European cohorts, placing GG homozygotes at the highest WFS1-locus risk. The Cheng et al. 2013 meta-analysis (PMID 23257691) of 12 studies (16,304 cases / 22,004 controls) confirmed dominant OR 0.853 for A, consistent with a ~17% per-G-allele risk elevation.

Critically, GG carriers who also carry the HNF4A P2-promoter risk allele (rs1884613) face a compounded 3-fold T2D risk elevation, as demonstrated in the Neuman et al. 2010 Ashkenazi Jewish cohort (PMID 20361036). The HNF4A P2 promoter drives WFS1 transcription in beta cells — reduced HNF4A-P2 activity further suppresses WFS1 in a GG background, creating a regulatory double-hit that substantially exceeds the additive individual effects.

Because the mechanism is ER-stress-mediated secretory impairment, this risk is orthogonal to insulin-resistance variants: carriers of both impaired-secretion and impaired-sensitivity alleles face multiplicatively higher risk.